ReviewAdvances in biochemical engineering/biotechnology2026
Bioprocess Engineering for Cultivated Meat.
Review in Advances in biochemical engineering/biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cultivated meat (CM) has emerged as a promising solution to the environmental, ethical, and food security concerns associated with conventional meat production. However, realising its full potential depends on developing robust, scalable, and cost-effective bioprocessing strategies. This chapter explores the entire CM bioprocessing pipeline, from upstream challenges such as the development of robust cell lines, scaling up cell cultures, and evaluating different operating modes like batch, fed-batch, and perfusion to downstream processes such as biomass harvesting, purification, and product structuring. Key considerations include ensuring sterility, monitoring critical process parameters, and supporting effective cell proliferation and differentiation. Economically, the high cost of media and capital expenditures remain a major barrier to scale. Strategies such as media recycling, bulk ingredient sourcing, and in-house production are being explored to reduce costs. Emerging technologies like artificial intelligence, machine learning, and digital twins offer new tools for optimising operations, though adoption is still in early stages. As the industry progresses toward commercialisation, continued innovation in bioprocess engineering, guided by techno-economic modelling, will be crucial to achieving scalable and sustainable meat alternatives.
Indexed as
Identifiers
41087815What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.